课题基金 / 基金详情

Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1

Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
瞄准内毒素相关肺损伤的新靶点：ICAM-1 的 Ig 结构域 3
批准号：
479050
负责人：
Zhang Haibo
金额：
$71.56万
依托单位：
Unity Health Toronto
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2028-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=479050&lang=en
关键词：
Microbiology& Infection Diseases

项目摘要

项目成果

Zhang Haibo的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Acute respiratory distress syndrome (ARDS) is the worst form of acute lung injury, and is a leading cause of death in critically ill patients. Sepsis, a life threatening complication of infection, is the major cause of ARDS. Approximately 50% of patients
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aiming at a novel target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
  • 批准号：
    477251
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2022
  • 负责人：
    Zhang Haibo
  • 依托单位：
    Unity Health Toronto
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)